See Full Document Text
Official Journal EN
of the European Union L series
2024/2684 11.10.2024
COMMISSION DELEGATED REGULATION (EU) 2024/2684
of 2 February 2024
amending Delegated Regulation (EU) 2016/127 as regards the protein-related requirements for infant
and follow-on formula manufactured from protein hydrolysates
(Text with EEA relevance)
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013on food
intended for infants and young children, food for special medical purposes and total diet replacement for weight control
and repealing Council Directive 92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC
and 2006/141/EC, Directive 2009/39/EC of the European Parliament and of the Council and Commission Regulations
(EC) No 41/2009 and (EC) No 953/2009(1), and in particular Article 11(2) thereof,
Whereas:
(1) Commission Delegated Regulation (EU) 2016/127(2) lays down specific compositional requirements for infant
formula and follow-on formula manufactured from protein hydrolysates. It provides that infant formula and
follow-on formula manufactured from protein hydrolysates are to comply with the requirements for protein
content, protein source, protein processing as well as with the requirements for indispensable and conditionally
indispensable amino acids and L-carnitine as set out in point 2.3 of Annex I and in point 2.3 of Annex II to that
Regulation.
(2) As stated in Delegated Regulation (EU) 2016/127, in its opinion of 24 July 2014 on the essential composition of
infant and follow-on formulae(3), the European Food Safety Authority (‘the Authority’) noted that the safety and
suitability of each specific formula containing protein hydrolysates have to be established by clinical evaluation in
the target population. So far, the Authority has positively evaluated three protein hydrolysates used in infant and
follow-on formulae. The composition of those three protein hydrolysates is reflected in the requirements currently
set out in Delegated Regulation (EU) 2016/127. However, those requirements may be updated in order to allow the
placing on the market of a formula manufactured from protein hydrolysates with a different composition from those
already positively assessed, following a case-by-case evaluation by the Authority of their safety and suitability.
(3) On 6 December 2019, the Commission received a request from FrieslandCampina Nederland B.V. for the evaluation
by the Authority of the safety and suitability of two products, an infant and follow-on formula manufactured from a
specific protein hydrolysate, the composition of which did not comply with the requirements laid down in point 2.3
of Annex I and in point 2.3 of Annex II to Delegated Regulation (EU) 2016/127.
(1) OJ L 181, 29.6.2013, p. 35.
(2) Commission Delegated Regulation (EU) 2016/127 of 25 September 2015 supplementing Regulation (EU) No 609/2013 of the
European Parliament and of the Council as regards the specific compositional and information requirements for infant formula and
follow-on formula and as regards requirements on information relating to infant and young child feeding (OJ L 25, 2.2.2016, p. 1).
(3) EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2014. Scientific Opinion on the essential composition of
infant and follow-on formulae. EFSA Journal 2014;12(7):3760.
ELI: http://data.europa.eu/eli/reg_del/2024/2684/oj 1/8EN
OJ L, 11.10.2024
(4) Upon request from the Commission, the Authority issued a scientific opinion on 18 July 2023on the nutritional
safety and suitability of that infant and follow-on formula(4). In that opinion, the Authority concluded that the
protein hydrolysate in question is a nutritionally safe and suitable protein source for use in infant and follow-on
formula, as long as the formula in which it is used contains a minimum of 0,57 g/100 kJ (2,4 g/100 kcal) protein
and complies with the other compositional criteria set out in Delegated Regulation (EU) 2016/127 and with the
amino acid pattern contained in Section A of Annex III to that Regulation.
(5) Taking into account the Authority’s conclusions, it is appropriate to allow the placing on the market of infant and
follow-on formula manufactured from the specific protein hydrolysate as described in the opinion. Therefore, the
requirements for protein hydrolysates set out in Regulation (EU) 2016/127 should be updated and adapted to also
include the requirements for the specific protein hydrolysate as described in the opinion.
(6) Annexes I, II and III to Delegated Regulation (EU) 2016/127 should therefore be amended accordingly.
(7) Delegated Regulation (EU) 2016/127 applies to infant formula and follow-on formula manufactured from protein
hydrolysates as of 22 February 2022. In order to allow the placing on the market of infant and follow-on formula
manufactured from hydrolysed protein in accordance with the requirements set out in this Regulation without
unnecessary delay, this Regulation should enter into force as a matter of urgency,
HAS ADOPTED THIS REGULATION:
Article 1
Annexes I, II and III to Delegated Regulation (EU) 2016/127 are amended in accordance with the Annex to this Regulation.
Article 2
This Regulation shall enter into force on the day of its publication in the Official Journal of the European Union.
This Regulation shall be binding in its entirety and directly applicable in all Member States.
Done at Brussels, 2 February 2024.
For the Commission
The President
Ursula VON DER LEYEN
(4) EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens), 2023. Nutritional safety and suitability of a specific
protein hydrolysate derived from whey protein concentrate and used in an infant formula and follow-on formula manufactured from
hydrolysed protein by FrieslandCampina Nederland B.V. EFSA Journal 2023;21(7):8063.
2/8 ELI: http://data.europa.eu/eli/reg_del/2024/2684/ojEN
OJ L, 11.10.2024
ANNEX
Annexes I, II and III to Delegated Regulation (EU) 2016/127 are amended as follows:
(1) in Annex I, point 2.3 is replaced by the following:
‘2.3. Infant formula manufactured from protein hydrolysates
Infant formula manufactured from protein hydrolysates shall comply with the protein-related requirements
provided under point 2.3.1, point 2.3.2, point 2.3.3 or point 2.3.4.
2.3.1. Protein-related requirements group A
2.3.1.1. Protein content
Minimum Maximum
0,44g/100kJ 0,67g/100kJ
(1,86g/100kcal) (2,8g/100kcal)
2.3.1.2. Protein source
Demineralised sweet whey protein derived from cows’ milk after enzymatic precipitation of
caseins using chymosin, consisting of:
(a) 63 % caseino-glycomacropeptide-free whey protein isolate with a minimum protein
content of 95 % of dry matter and protein denaturation of less than 70 % and a
maximum ash content of 3 %; and
(b) 37 % sweet whey protein concentrate with a minimum protein content of 87 % of dry
matter and protein denaturation of less than 70 % and a maximum ash content of 3,5 %.
2.3.1.3. Protein processing
Two-stage hydrolysis process using a trypsin preparation with a heat-treatment step (from 3
to 10 minutes at 80 to 100 °C) between the two hydrolysis steps.
2.3.1.4. Indispensable and conditionally indispensable amino acids and L-carnitine
For an equal energy value, infant formula manufactured from protein hydrolysates must
contain an available quantity of each indispensable and conditionally indispensable amino
acid at least equal to that contained in the reference protein as set out in Section B of
Annex III. Nevertheless, for calculation purposes, the concentration of methionine and
cysteine may be added together if the methionine:cysteine ratio is not greater than 2, and
the concentration of phenylalanine and tyrosine may be added together if the tyrosine:
phenylalanine ratio is not greater than 2. The ratio of methionine:cysteine and of tyrosine:
phenylalanine may be greater than 2, provided that the suitability of the product concerned
for infants is demonstrated in accordance with Article 3(3).
The L-carnitine content shall be at least equal to 0,3 mg/100 kJ (1,2 mg/100 kcal).
ELI: http://data.europa.eu/eli/reg_del/2024/2684/oj 3/8EN
OJ L, 11.10.2024
2.3.2. Protein-related requirements group B
2.3.2.1. Protein content
Minimum Maximum
0,55g/100kJ 0,67g/100kJ
(2,3g/100kcal) (2,8g/100kcal)
2.3.2.2. Protein source
Whey protein derived from cows’ milk, consisting of:
(a) 77 % acid whey, coming from whey protein concentrate with a protein content of 35 to
80 %;
(b) 23 % sweet whey, coming from demineralised sweet whey with a minimum protein
content of 12,5 %.
2.3.2.3. Protein processing
The source material is hydrated and heated. Following the heat-treatment step, the hydrolysis
is carried out at a pH of 7,5 to 8,5 and a temperature of 55 to 70 °C with the use of an
enzyme mixture of a serine endopeptidase and a protease/peptidase complex. The food
enzymes are inactivated in a heat-treatment step (from 2 to 10 seconds at 120 to 150 °C)
during the production process.
2.3.2.4. Indispensable and conditionally indispensable amino acids and L-carnitine
For an equal energy value, infant formula manufactured from protein hydrolysates must
contain an available quantity of each indispensable and conditionally indispensable amino
acid at least equal to that contained in the reference protein as set out in Section A of
Annex III. Nevertheless, for calculation purposes, the concentration of methionine and
cysteine may be added together if the methionine: cysteine ratio is not greater than 2, and
the concentration of phenylalanine and tyrosine may be added together if the tyrosine:
phenylalanine ratio is not greater than 2. The ratio of methionine:cysteine and of tyrosine:
phenylalanine may be greater than 2, provided that the suitability of the product concerned
for infants is demonstrated in accordance with Article 3(3).
The L-carnitine content shall be at least equal to 0,3 mg/100 kJ (1,2 mg/100 kcal).
2.3.3. Protein-related requirements group C
2.3.3.1. Protein content
Minimum Maximum
0,45g/100kJ 0,67g/100kJ
(1,9g/100kcal) (2,8g/100kcal)
2.3.3.2. Protein source
Whey protein derived from cows’ milk, consisting of 100 % sweet whey protein concentrate
with a minimum protein content of 80 %.
4/8 ELI: http://data.europa.eu/eli/reg_del/2024/2684/ojEN
OJ L, 11.10.2024
2.3.3.3. Protein processing
The source material is hydrated and heated. Prior to the hydrolysis, the pH is adjusted to
6,5–7,5 at a temperature of 50–65 °C. The hydrolysis is carried out with the use of an
enzyme mixture of a serine endopeptidase and a metalloprotease. The food enzymes are
inactivated in a heat-treatment step (from 2 to 10 seconds at 110 to 140 °C) during the
production process.
2.3.3.4. Indispensable and conditionally indispensable amino acids and L-carnitine
For an equal energy value, infant formula manufactured from protein hydrolysates must
contain an available quantity of each indispensable and conditionally indispensable amino
acid at least equal to that contained in the reference protein as set out in Section A of
Annex III. Nevertheless, for calculation purposes, the concentration of methionine and
cysteine may be added together if the methionine: cysteine ratio is not greater than 2, and
the concentration of phenylalanine and tyrosine may be added together if the tyrosine:
phenylalanine ratio is not greater than 2. The ratio of methionine:cysteine and of tyrosine:
phenylalanine may be greater than 2, provided that the suitability of the product concerned
for infants is demonstrated in accordance with Article 3(3).
The L-carnitine content shall be at least equal to 0,3 mg/100 kJ (1,2 mg/100 kcal).
2.3.4. Protein-related requirements group D
2.3.4.1. Protein content
Minimum Maximum
0,57g/100kJ 0,67g/100kJ
(2,4g/100kcal) (2,8g/100kcal)
2.3.4.2. Protein source
Whey protein derived from cow’s milk, consisting of 100 % sweet whey protein concentrate
with a minimum protein content of 70 %.
2.3.4.3. Protein processing
The source material is hydrated and heated. Following the heat-treatment step, the hydrolysis
is carried out at a pH of 7,0 to 8,0 and a temperature of 50 to 60 °C, using a two-stage
hydrolysis process with the use of a serine endopeptidase and a metalloprotease. The food
enzymes are inactivated by heat treatment (at 100 to 120 °C for at least 30 seconds) during
the production process.
2.3.4.4. Indispensable and conditionally indispensable amino acids and L-carnitine
For an equal energy value, infant formula manufactured from protein hydrolysates must
contain an available quantity of each indispensable and conditionally indispensable amino
acid at least equal to that contained in the reference protein as set out in Section A of
Annex III. Nevertheless, for calculation purposes, the concentration of methionine and
cysteine may be added together if the methionine: cysteine ratio is not greater than 2, and
the concentration of phenylalanine and tyrosine may be added together if the tyrosine:
phenylalanine ratio is not greater than 2. The ratio of methionine:cysteine and of tyrosine:
phenylalanine may be greater than 2, provided that the suitability of the product concerned
for infants is demonstrated in accordance with Article 3(3).
ELI: http://data.europa.eu/eli/reg_del/2024/2684/oj 5/8EN
OJ L, 11.10.2024
The L-carnitine content shall be at least equal to 0,3 mg/100 kJ (1,2 mg/100 kcal).’;
(2) in Annex II, point 2.3 is replaced by the following:
‘2.3. Follow-on formula manufactured from protein hydrolysates
Follow-on formula manufactured from protein hydrolysates shall comply with the protein-related requirements
provided under point 2.3.1, point 2.3.2, point 2.3.3 or point 2.3.4.
2.3.1. Protein-related requirements group A
2.3.1.1. Protein content
Minimum Maximum
0,44g/100kJ 0,67g/100kJ
(1,86g/100kcal) (2,8g/100kcal)
2.3.1.2. Protein source
Demineralised sweet whey protein derived from cows’ milk after enzymatic precipitation of
caseins using chymosin, consisting of:
(a) 63 % caseino-glycomacropeptide-free whey protein isolate with a minimum protein
content of 95 % of dry matter and protein denaturation of less than 70 % and a
maximum ash content of 3 %; and
(b) 37 % sweet whey protein concentrate with a minimum protein content of 87 % of dry
matter and protein denaturation of less than 70 % and a maximum ash content of 3,5 %.
2.3.1.3. Protein processing
Two-stage hydrolysis process using a trypsin preparation with a heat-treatment step (from 3
to 10 minutes at 80 to 100 °C) between the two hydrolysis steps.
2.3.1.4. Indispensable and conditionally indispensable amino acids
For an equal energy value, follow-on formula manufactured from protein hydrolysates must
contain an available quantity of each indispensable and conditionally indispensable amino
acid at least equal to that contained in the reference protein as set out in Section B of
Annex III. Nevertheless, for calculation purposes, the concentration of methionine and
cysteine and the concentration of phenylalanine and tyrosine may be added together.
2.3.2. Protein-related requirements group B
2.3.2.1. Protein content
Minimum Maximum
0,55g/100kJ 0,67g/100kJ
(2,3g/100kcal) (2,8g/100kcal)
2.3.2.2. Protein source
Whey protein derived from cows’ milk, consisting of:
(a) 77 % acid whey, coming from whey protein concentrate with a protein content of 35 to
80 %;
(b) 23 % sweet whey, coming from demineralised sweet whey with a minimum protein
content of 12,5 %.
6/8 ELI: http://data.europa.eu/eli/reg_del/2024/2684/ojEN
OJ L, 11.10.2024
2.3.2.3. Protein processing
The source material is hydrated and heated. Following the heat-treatment step, the hydrolysis
is carried out at a pH of 7,5 to 8,5 and a temperature of 55 to 70 °C with the use of an
enzyme mixture of a serine endopeptidase and a protease/peptidase complex. The food
enzymes are inactivated in a heat-treatment step (from 2 to 10 seconds at 120 to 150 °C)
during the production process.
2.3.2.4. Indispensable and conditionally indispensable amino acids
For an equal energy value, follow-on formula manufactured from protein hydrolysates must
contain an available quantity of each indispensable and conditionally indispensable amino
acid at least equal to that contained in the reference protein as set out in Section A of
Annex III. Nevertheless, for calculation purposes, the concentration of methionine and
cysteine and the concentration of phenylalanine and tyrosine may be added together.
2.3.3. Protein-related requirements group C
2.3.3.1. Protein content
Minimum Maximum
0,45g/100kJ 0,67g/100kJ
(1,9g/100kcal) (2,8g/100kcal)
2.3.3.2. Protein source
Whey protein derived from cows’ milk, consisting of 100 % sweet whey protein concentrate
with a minimum protein content of 80 %.
2.3.3.3. Protein processing
The source material is hydrated and heated. Prior to the hydrolysis, the pH is adjusted to
6,5–7,5 at a temperature of 50–65 °C. The hydrolysis is carried out with the use of an
enzyme mixture of a serine endopeptidase and a metalloprotease. The food enzymes are
inactivated in a heat-treatment step (from 2 to 10 seconds at 110 to 140 °C) during the
production process.
2.3.3.4. Indispensable and conditionally indispensable amino acids
For an equal energy value, follow-on formula manufactured from protein hydrolysates must
contain an available quantity of each indispensable and conditionally indispensable amino
acid at least equal to that contained in the reference protein as set out in Section A of
Annex III. Nevertheless, for calculation purposes, the concentration of methionine and
cysteine and the concentration of phenylalanine and tyrosine may be added together.
2.3.4. Protein-related requirements group D
2.3.4.1. Protein content
Minimum Maximum
0,57g/100kJ 0,67g/100kJ
(2,4g/100kcal) (2,8g/100kcal)
ELI: http://data.europa.eu/eli/reg_del/2024/2684/oj 7/8EN
OJ L, 11.10.2024
2.3.4.2. Protein source
Whey protein derived from cow’s milk, consisting of 100 % sweet whey protein concentrate
with a minimum protein content of 70 %.
2.3.4.3. Protein processing
The source material is hydrated and heated. Following the heat-treatment step, the hydrolysis
is carried out at a pH of 7,0 to 8,0 and a temperature of 50 to 60 °C, using a two-stage
hydrolysis process with the use of a serine endopeptidase and a metalloprotease. The food
enzymes are inactivated by heat treatment (at 100 to 120 °C for at least 30 seconds) during
the production process.
2.3.4.4. Indispensable and conditionally indispensable amino acids
For an equal energy value, follow-on formula manufactured from protein hydrolysates must
contain an available quantity of each indispensable and conditionally indispensable amino
acid at least equal to that contained in the reference protein as set out in Section A of
Annex III. Nevertheless, for calculation purposes, the concentration of methionine and
cysteine and the concentration of phenylalanine and tyrosine may be added together.’.
(3) in Annex III, the introductory sentence under section A is replaced by the following:
‘For the purposes of points 2.1, 2.2, 2.3.2, 2.3.3 and 2.3.4 of Annexes I and II, the indispensable and conditionally
indispensable amino acids in breast milk, expressed in mg per 100 kJ and 100 kcal, are the following:’.
8/8 ELI: http://data.europa.eu/eli/reg_del/2024/2684/oj